Balchem Clocks 13% Sales Growth In Q3, Tops Consensus

  • Balchem Corp BCPC reported third-quarter FY21 sales growth of 13% year-on-year, to $197.87 million, beating the analyst consensus of $196.13 million.
  • Sales from Human Nutrition and Health segment rose 7.3% Y/Y to $111.2 million, Animal Nutrition and Health increased 21.2% to $56.2 million, and Specialty Products grew 20% to $27.6 million.
  • The gross margin increased 8.1% Y/Y to $60.9 million, with the margin contracting 139 basis points 30.7%.
  • The operating margin was 16.4%, and operating income for the quarter rose 12% to $32.5 million.
  • Balchem held $90 million in cash and equivalents as of September 30, 2021. Cash flow from operations totaled $39.6 million with a free cash flow of $31.1 million.
  • Adjusted EPS of $0.92 beat the analyst consensus of $0.90.
  • Adjusted EBITDA was $48.3 million, an increase of 8.8% Y/Y.
  • "We expect these macro-economic challenges, including global supply chain disruptions and input cost inflation, to continue to accelerate into the fourth quarter and next year, and mitigating these impacts will remain a key focus for the Balchem team," said Ted Harris, Chairman, CEO, and President of Balchem.
  • Price Action: BCPC shares are trading lower by 0.39% at $152.58 on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!